Equities research analysts at Jefferies Group initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note issued on Tuesday, March 20th, MarketBeat reports. The firm set a “hold” rating and a $19.00 price target on the stock. Jefferies Group’s price objective would indicate a potential upside of 4.51% from the company’s current price. Jefferies Group also issued estimates for Teva Pharmaceutical Industries’ Q1 2018 earnings at $0.58 EPS, Q2 2018 earnings at $0.52 EPS, Q3 2018 earnings at $0.49 EPS, Q4 2018 earnings at $0.51 EPS and FY2018 earnings at $2.32 EPS.
Other equities research analysts have also recently issued research reports about the company. BTIG Research cut Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 price target for the company. in a report on Friday, February 2nd. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Leerink Swann cut their price target on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating for the company in a report on Friday, February 9th. Piper Jaffray cut Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 price target for the company. in a report on Friday, February 9th. Finally, Cantor Fitzgerald set a $18.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Wednesday, January 3rd. Eleven equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $19.67.
Shares of NYSE:TEVA traded up $0.19 during midday trading on Tuesday, hitting $18.18. The company had a trading volume of 9,160,212 shares, compared to its average volume of 15,388,455. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $33.82. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.58 and a current ratio of 0.86. The stock has a market cap of $18,181.76, a PE ratio of 4.63, a P/E/G ratio of 1.56 and a beta of 0.67.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The firm had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the firm earned $1.38 earnings per share. The business’s revenue for the quarter was down 15.9% on a year-over-year basis. analysts predict that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current fiscal year.
In other news, EVP Mark Sabag sold 5,050 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the completion of the transaction, the executive vice president now directly owns 44,517 shares in the company, valued at $876,094.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have sold 10,734 shares of company stock valued at $204,795. Company insiders own 7.10% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. boosted its holdings in Teva Pharmaceutical Industries by 8.2% in the fourth quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock valued at $1,506,309,000 after purchasing an additional 6,009,897 shares during the period. Two Sigma Advisers LP purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $118,487,000. Schroder Investment Management Group boosted its holdings in Teva Pharmaceutical Industries by 22.7% in the third quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock valued at $106,290,000 after purchasing an additional 1,147,683 shares during the period. OppenheimerFunds Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $69,418,000. Finally, Swiss National Bank boosted its holdings in Teva Pharmaceutical Industries by 0.9% in the fourth quarter. Swiss National Bank now owns 3,523,499 shares of the company’s stock valued at $66,770,000 after purchasing an additional 32,000 shares during the period. Hedge funds and other institutional investors own 58.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first published by Macon Daily and is the property of of Macon Daily. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://macondaily.com/2018/04/12/teva-pharmaceutical-industries-teva-receives-new-coverage-from-analysts-at-jefferies-group-updated-updated-updated.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.